BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37199346)

  • 21. Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis.
    Donovan EK; Parpia S; Greenspoon JN
    Curr Oncol; 2019 Jun; 26(3):e328-e333. PubMed ID: 31285676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship of dose-volume histogram parameters and computed tomography grading of radiation-induced lung injury in patients with non-small cell lung cancer treated by three-dimensional conformal radiotherapy].
    Xing J; Li JB; Yu JM; Lu J; Xu M; Fan TY; Shao Q; Guo SF
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):676-81. PubMed ID: 19173909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
    Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
    Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review.
    Sharma A; Mountjoy LJ; Butterfield RJ; Zhang N; Ross HJ; Schild SE; Sio TT; Daniels TB; Paripati HR; Mrugala MM; Vora SA; Patel NP; Zimmerman RS; Ashman JB; Porter AB
    Am J Clin Oncol; 2020 Feb; 43(2):128-132. PubMed ID: 31764021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.
    Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS
    Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Three-dimensional conformal hypofractionated radiotherapy for brain metastases of non-small-cell lung carcinoma: implications for whole brain irradiation].
    Qiu XS; Chen LH; Chen YQ
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1375-8. PubMed ID: 16305959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.
    Zhou L; Liu J; Xue J; Xu Y; Gong Y; Deng L; Wang S; Zhong R; Ding Z; Lu Y
    Radiat Oncol; 2014 May; 9():117. PubMed ID: 24884773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review.
    Li HS; Lei SY; Li JL; Xing PY; Hao XZ; Xu F; Xu HY; Wang Y
    Front Immunol; 2022; 13():908436. PubMed ID: 36105807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients.
    Lehrer EJ; Gurewitz J; Bernstein K; Kondziolka D; Fakhoury KR; Rusthoven CG; Niranjan A; Wei Z; Lunsford LD; Malouff TD; Ruiz-Garcia H; Peterson JL; Bonney P; Hwang L; Yu C; Zada G; Deibert CP; Prasad RN; Raval RR; Palmer JD; Patel S; Picozzi P; Franzini A; Attuati L; Mathieu D; Trudel C; Lee CC; Yang HC; Jones BM; Green S; Ahluwalia MS; Sheehan JP; Trifiletti DM
    Neurosurgery; 2022 Dec; 91(6):872-882. PubMed ID: 36255215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
    Le PĂ©choux C; Dunant A; Senan S; Wolfson A; Quoix E; Faivre-Finn C; Ciuleanu T; Arriagada R; Jones R; Wanders R; Lerouge D; Laplanche A;
    Lancet Oncol; 2009 May; 10(5):467-74. PubMed ID: 19386548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Minniti G; Scaringi C; Lanzetta G; Anzellini D; Bianciardi F; Tolu B; Morace R; Romano A; Osti M; Gentile P; Paolini S
    Lung Cancer; 2019 Jun; 132():119-125. PubMed ID: 31097084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
    Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis.
    Miller JA; Bennett EE; Xiao R; Kotecha R; Chao ST; Vogelbaum MA; Barnett GH; Angelov L; Murphy ES; Yu JS; Ahluwalia MS; Suh JH; Mohammadi AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1060-1069. PubMed ID: 27742540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
    Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
    Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    Li W; Yu H
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):137-152. PubMed ID: 31813004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy.
    Stanic K; Vrankar M; But-Hadzic J
    Radiol Oncol; 2020 Jul; 54(3):353-363. PubMed ID: 32726294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
    Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.